A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Summary

The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.

Timeline

Start

2011-03-01

Primary completion

2011-09-23

Completion

2011-09-23

Drugs

Indications